Article

Multispot laser system receives FDA clearance

The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA. It is intended to deliver a cost-effective solution to ophthalmologists dealing with epidemic levels of diabetic eye disease.

 

Clermont-Ferrand, France-The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA.  The product was developed by Quantel Medical to give access to advanced pattern-scanning technology to ophthalmology practices worldwide though intelligent design.

The laser combines advanced pattern scanning and solid-state green laser technologies in a compact portable platform to deliver a cost-effective solution to ophthalmologists around the world dealing with epidemic levels of diabetic eye disease in their patient populations, according to the company.

“The [multispot laser] has accelerated our capability to manage the growing number of diabetic patients coming to our practice for care and [has] improved our reputation for superior patient care since the pattern-scanning laser treatment . . . is less painful compared [with] the previous treatments many patients received with a conventional laser,” said Rama D. Jager, MD, MBA, FACS of University Retina, Oak Forest, IL, who was the first user of the Vitra Multispot in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
© 2025 MJH Life Sciences

All rights reserved.